For example, the SRC1 inhibitor elvitegravir disrupts the formation of SRC-1 condensates in cancer cells, presenting a promising LLPS-based strategy for targeting the traditionally challenging SRC-1/YAP/TEAD complex and suppressing YAP-dependent cancer proliferation 110. The gene discussed is NCOA1; the disease is cancer.